Publications by authors named "Diana J Cano Rosales"
Introduction Chronic Obstructive Pulmonary Disease (COPD) is a systemic disease characterized by skeletal muscle dysfunction, leading to increased morbidity and mortality and deteriorating quality of life. Pulmonary rehabilitation therapy improves symptoms and long-term adherence. This study aimed to evaluate how COPD patients respond to pulmonary rehabilitation therapy and its correlation with handgrip strength measurements.
View Article and Find Full Text PDFExploring Definitions and Predictors of Response to Biologics for Severe Asthma.
J Allergy Clin Immunol Pract
September 2024
Background: Biologic effectiveness is often assessed as response, a term that eludes consistent definition. Identifying those most likely to respond in real-life has proven challenging.
Objective: To explore definitions of biologic responders in adults with severe asthma and investigate patient characteristics associated with biologic response.
Article Synopsis
- The study investigates how pre-biologic biomarker levels, specifically immunoglobulin E (IgE), blood eosinophil count (BEC), and fractional exhaled nitric oxide (FeNO), influence asthma treatment outcomes when patients start biologic therapy.
- Conducted across 23 countries with over 3750 patients, the research focused on changes in exacerbation rates, symptom control, and lung function about a year after starting treatment.
- Results showed that higher levels of BEC and FeNO were linked to significant improvements in lung function for specific biologic therapies, while IgE was not a strong predictor of treatment effectiveness.
Article Synopsis
- There is currently no agreed-upon definition for asthma remission in real life, and the factors that help patients achieve it after starting biologics are not well understood.
- A study analyzed data from 23 countries to see how many adults with severe asthma reached multidomain-defined remission after beginning biologic treatment, using specific criteria for remission.
- Results showed that less than a quarter of participants achieved full remission, with higher chances for those with fewer exacerbations, lower corticosteroid use, and better control and lung function before treatment, suggesting that early intervention is crucial for better outcomes.
Article Synopsis
- Previous studies on how comorbidities affect the effectiveness of biologic agents in asthma were limited in size and duration, lacking comparisons between different biologic classes.
- This cohort study analyzed data from the International Severe Asthma Registry across 21 countries to assess changes in asthma outcomes after starting biologic therapy in patients with type 2-related comorbidities.
- Results showed that patients with chronic rhinosinusitis (CRS) and nasal polyps (NPs) experienced significantly better outcomes, including fewer exacerbations and improved asthma control, while allergic rhinitis and atopic dermatitis did not influence therapy effectiveness.
Article Synopsis
- The study aimed to evaluate the prevalence and impact of comorbidities in adults with severe asthma, as their presence can complicate asthma management practices.* -
- Data was analyzed from the International Severe Asthma Registry, identifying 30 comorbidities linked to asthma, with findings indicating a significant percentage of patients experience multiple comorbidities that affect their asthma outcomes.* -
- Results showed that patients with specific comorbidities like allergic rhinitis and nasal polyposis had higher rates of asthma exacerbations and were more likely to require long-term oral corticosteroids, highlighting the need for effective management strategies.*